Product Description
Mechanisms of Action: Voltage-Gated Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Ireland
Approved Indications: None
Known Adverse Events: None
Company: Hadassah Medical Organization
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
yc19551-HMO-CTIL | N/A |
Unknown status |
Healthy Volunteers |
2020-12-01 |